{"id":64984,"date":"2025-02-24T12:01:40","date_gmt":"2025-02-24T12:01:40","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/02\/24\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/"},"modified":"2025-02-24T12:01:40","modified_gmt":"2025-02-24T12:01:40","slug":"auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/","title":{"rendered":"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia"},"content":{"rendered":"<div>\n<p><em>Initiating Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025<\/em><\/p>\n<p align=\"left\">NEWTON, Mass., Feb.  24, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CF03HSG3Uy9UISubG6M4YB8ipBfx--Q02wDtq4RCQFNlry3jRNJzTsAXwjI8DzGjxELzKH1vIq9uW-B14c01Xg==\" rel=\"nofollow\" target=\"_blank\" title=\"Auron Therapeutics\">Auron Therapeutics<\/a>, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Fast Track designation to AUTX-703 for the treatment of patients with relapsed or refractory (r\/r) acute myelogenous leukemia (AML).<\/p>\n<p>AUTX-703 is a novel, first-in-class, oral KAT2A\/B degrader discovered and developed by Auron using its AURIGIN&#x2122; Platform. The Company <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7NHyaQTZKxRN4z7hzanPyaSleJ4TtPU-lBMLUrCJOFYax-GEtbsOQ9nPU50aDCNMVZ0qeyz2F1tRcUpauOvmkxOeKQx63F3oYeNChB7HwvVd4K6SvnKAP_y0Zc95TDAU3VPPAV6pTH21IMITmdExBLnfykEnqi6D0HwK64Ls-wQzbcbjtJ2UTLoOjLJsNDcPgqt8c6F7ViwBp8_wud4SrA==\" rel=\"nofollow\" target=\"_blank\" title=\"has previously presented\">has previously presented<\/a> preclinical data supporting the ability of AUTX-703 to provide a significant survival advantage in AML. Following the FDA\u2019s recent clearance of its Investigational New Drug (IND) application, Auron plans to initiate clinical development of AUTX-703 in hematological malignancies in the first quarter of 2025.<\/p>\n<p>\u201cWe are gratified by the FDA\u2019s recognition of AUTX-703\u2019s potential as an important, novel treatment option for relapsed or refractory AML patients, a community that remains in desperate need of new therapies,\u201d said Kate Yen, Ph.D., Founder and Chief Executive Officer of Auron. \u201cThe FDA Fast Track Designation underscores the urgent need for innovative treatments for these patients and this milestone comes at a pivotal moment as we prepare to advance AUTX-703 into the clinic. Our team is energized by the potential to bring a first-in-class therapy to patients who have limited effective options today, while simultaneously exploring the broader applications of KAT2A\/B modulation.\u201d<\/p>\n<p>The\u00a0FDA\u2019s\u00a0Fast Track program is designed to facilitate the development and expedite the review of medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs. Specifically, Fast Track designation facilitates more frequent interactions with the\u00a0FDA\u00a0over the course of a drug\u2019s development and enables Accelerated Approval and Priority Review eligibility, if relevant criteria are met.<\/p>\n<p>AML is an aggressive blood cancer characterized by the rapid growth of abnormal cells that build up in the bone marrow and interfere with normal blood cell production. Patients with relapsed or refractory AML face particularly poor outcomes, with five-year survival rates of approximately 10%<sup>1<\/sup>, highlighting the critical need for novel therapeutic approaches.<\/p>\n<p><strong>About Auron Therapeutics<\/strong><\/p>\n<p>Auron Therapeutics is a platform-powered, product-driven company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease. Auron pioneered its AURIGIN&#x2122; platform, which uses AI and machine learning to compare cell states and identify novel drug targets, optimal development models, and biomarkers to facilitate proper patient selection, ultimately accelerating the development of effective and durable therapies. Using AURIGIN, the Company is building a pipeline of small molecule targeted therapies, led by a first-in-class, oral KAT2A\/B degrader, AUTX-703, which is being developed for the treatment of both hematologic malignancies and solid tumors. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=99fRITH_6-5DNQTLEHdvggUpIOuf63EOW-dUmmv0pbBAAHtU0mOBnxqzcDOSg6zpP3H6bLjwAg-JRjgc8EAg8g==\" rel=\"nofollow\" target=\"_blank\" title=\"aurontx.com\">aurontx.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LFnV2p-Dv0qLulEYZfAc3Ss5sBizfiyv5hdEOMmIhews4UOdrx7bpnh6yePIELeHT4BV0hj8dXdltCwdkRHF2IwxmPPIbZmKXq2cfBHKrPhr3HbB1rxD8Aw52IC1qTn5\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>.<\/p>\n<p><strong>Investor Contact:<\/strong><\/p>\n<p>Renee Leck<br \/>THRUST Strategic Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RaBayjZJwtIt6XzJd4QynGuHI0IqZ_zcaV2um45C1NEn8w4aDPQFr6bNkF6x6tVO9S-SnU0LF30JMbHCWkookAf0SzyQoCSrZkA3HhCKjHU=\" rel=\"nofollow\" target=\"_blank\" title=\"renee@thrustsc.com\">renee@thrustsc.com<\/a><\/p>\n<p><strong>Media Contact:<\/strong><\/p>\n<p>Carly Scaduto<br \/>Carly Scaduto Consulting<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2B6MI4oUX8FN8F9-TzfI_7cTvKU3LBuQccf1tq-p4ozU-YjczaGZWqEkbUJo3_QC7t75wxUZxRaUg8nmfgfs-tGpPxAwDtLURkl9lEsP785DX3Ox30KFYT2inaZsopOh\" rel=\"nofollow\" target=\"_blank\" title=\"Carly@carlyscadutoconsulting.com\">Carly@carlyscadutoconsulting.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTMzNzE3OWItY2IyNS00OTBhLWE3ZGItYzUwOGNmYjQ1ZjQ2LTEyMTc5OTQ=\/tiny\/Auron-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Initiating Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 NEWTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) &#8212; Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Fast Track designation to AUTX-703 [&#8230;]\n","protected":false},"author":1,"featured_media":64985,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-64984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia\" \/>\n<meta property=\"og:description\" content=\"Initiating Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 NEWTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) &amp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T12:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/02\/Auron-Therapeutics-Inc-1-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia\",\"datePublished\":\"2025-02-24T12:01:40+00:00\",\"dateModified\":\"2025-02-24T12:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\"},\"wordCount\":511,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\",\"name\":\"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-02-24T12:01:40+00:00\",\"dateModified\":\"2025-02-24T12:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia","og_description":"Initiating Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025 NEWTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) &","og_url":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-02-24T12:01:40+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/02\/Auron-Therapeutics-Inc-1-1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia","datePublished":"2025-02-24T12:01:40+00:00","dateModified":"2025-02-24T12:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/"},"wordCount":511,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/","url":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/","name":"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-02-24T12:01:40+00:00","dateModified":"2025-02-24T12:01:40+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=64984"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/64984\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/64985"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=64984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=64984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=64984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}